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Sllmmary 
The major target of the neutralizing antibody response to infection by the human immunodeficiency 
virus type 1 (HIV-1) is the outer envelope glycoprotein, gp120. The spectrum of HIV-1 neutral- 
ization specificity is currently represented by monoclonal antibodies (mAbs) that can be divided 
broadly into five groups. We have studied the binding of these mAbs to functional oligomeric 
and soluble monomeric gp120 derived from the molecular clone of a cell line-adapted isolate 
of HIV-1, and compared these binding properties with virus neutralization.  Binding of all mAbs 
except those reactive with the V3 loop was much weaker to oligomeric than to monomeric 
gp120. This reduction in binding to oligomeric gp120 was determined mostly by a slower rela- 
tive rate of association, although the dissociation rate also had some influence on relative varia- 
tion in mAb affinity. Virus neutralization  correlated broadly with mAb binding to the oligo- 
meric rather than to the monomeric form of gp120, and neutralization  potency was related to 
the estimated association rate. Thus, with the exception of the hypervariable V3 loop, regions 
of HIV-1 gp120 with the potential  to induce a neutralization  response are likely to be poorly 
presented for antibody recognition on the surface of cell line-adapted virions. 
T 
he surface envelope glycoprotein (gp120) of the human 
immunodeficiency  virus HIV-1 is essential for receptor 
binding and viral entry into permissive cells (1, 2). In addi- 
tion, it is the major target for neutralizing antibodies in vitro 
and in vivo and thus is an important element in vaccine de- 
velopment (3). Neutralizing antisera and mAbs have been 
raised against gp120 in the form of recombinant or purified 
glycoprotein or synthetic peptides, or during natural infec- 
tion with the virus (4-27).  For many mAbs, their epitopes 
have been mapped by analysis of their binding to synthetic 
peptides (5-16,  18, 21, 22, 24), recombinant glycoproteins 
containing site-directed mutations (25-27), or a combination 
of both strategies (19, 20, 23). Such analyses have allowed 
a partial understanding of the exposure and spatial relation- 
ship of these mAb epitopes on gp120 (19, 20,  22-28). 
To date, five  different dusters of mAbs that define domi- 
nant neutralizing epitopes on gp120 have been described. The 
V3 loop has been considered for some time as the immuno- 
dominant neutralization domain, and V3-reactive mAbs or 
antisera can potently neutralize HIV-1 (4-16). In general, neu- 
tralization  via this domain is highly type specific, although 
some recent reports demonstrate that a broader neutralizing 
response can be obtained  (15, 29-32).  Several neutralizing 
mAbs reactive with the second variable domain (V2) of gp120 
have been described (17, 18, 20), and their epitopes have been 
defined in detail (19, 20, 33). The fourth conserved domain 
of gp120 (C4)  has been implicated  as contributing to the 
binding surface for CD4 (34-36).  In accord with this pro- 
posal is the finding that mAbs reactive with this region in- 
hibit the interaction between recombinant gp120 and CD4 
(22) and neutralize in a group-specific manner (21-23, 34). 
Another group of neutralizing mAbs of  human origin overhps 
broadly with the CD4 binding domain of gp120 (24-26, 
37-40). These mAbs map to conformationally  sensitive, dis- 
continuous epitopes as indicated by extensive mutational anal- 
yses (25, 26). Like the C4-reactive mAbs,  these mAbs in- 
hibit the interaction  of CD4 with monomeric gp120 (24) 
or virus  with CD4 § cells (38). Other neutralization  do- 
mains that also have discontinuous, conformational epitopes 
but that do not interfere with virus-receptor binding have 
recently been defined by human mAbs (41); indeed,  these 
mAbs bind better to soluble CD4 (sCD4)l-gp120 complexes 
than to gp120 alone (27). 
The external envelope  glycoprotein is expressed  on the virion 
surface in an oligomeric form, most probably a tetramer, in 
association  with  the  transmembrane  glycoprotein  gp41 
1 Abbreviations used in this paper: sCD4, soluble CD4; TBS, Tris-buffered 
saline; WB,  PBS/1% FCS; X-Gal, 5-bromo-4-chloro-3-indolyl-B-D- 
galactopyranoside. 
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accessible on the monomeric form of gpl20 will be masked 
or presented in a different conformation on the functional, 
virion-associated form. Since it is the availability of an epi- 
tope on the virion surface that will influence antibody neu- 
tralization activity, it is important to study antibody-gpl20 
interactions in a system where the viral envelope glycopro- 
teins are presented in their native, functional form. Immu- 
noelectron microscopic analysis of the surface of certain virus- 
infected cell lines such as H9 shows that the majority of viral 
envelope glycoprotein present on cell membranes  is in the 
form of adherent virus particles (46 and Sattentau,  Q.,  un- 
published data).  Moreover, such virus-infected cells readily 
fuse with CD4 §  cells to form syncytia (1, 47).  The enve- 
lope glycoproteins on the surface of HIV-l-infected ceils are 
therefore likely to be representative of those on virions, both 
in terms of function and antigenic presentation. For this reason 
we have chosen to  study gpl20  on the  surface of cells in- 
fected with the HIV-1 molecular clone Hxl0 derived from 
the LAI isolate. 
The data that we present here demonstrate that neutralizing 
mAb epitopes, with the exception of the V3 loop, are rela- 
tively poorly presented on the surface of functional HIV-1 
gpl20  oligomers,  and that  mAb  affinity for these epitopes 
relates directly to their ability to neutralize virus infection. 
Materials  and Methods 
Antibodies.  The anti-gp120/V3 mAbs were obtained from the 
following sources: 110.I (28) from F. Traincard (Hybridolab, Pasteur 
Institute, Paris, France);  110.5 (9) from Genetic Systems (Seattle, 
WA); 9284 (8) from DuPont de Nemours (Les Ulis, France); BAT123 
(4,  12) from Tanox Biosystems  Inc. (Houston, TX) and D.  Ho 
(Aaron Diamond AIDS Research Center, New York); and 8/38c 
(16) from C. Dean and C. Shotton (Institute for Cancer Research, 
Surrey, UK). The anti-gp120/V2 mAbs BAT085, G3-136 (18), and 
G3-4 (17), and anti-C4 mAbs G3-42, G3-519,  G3-299, and G3- 
536 (21, 23) were also from Tanox Biosystems  Inc.  and D.  Ho. 
The human mAbs 15e, 21h (24), 48d, and 17b (27, 41) were from 
J. Robinson (University of Connecticut, Storrs, CT). Antisera were 
from the following sources: human anti-HIV QC1, QC2, and QC5 
(48) from P. Clapham (Chester Beatty Laboratories, London, UK); 
infected laboratory worker serum  from W.  Blattner  (National 
Cancer Institute, Frederick, MD) (49); rabbit anti-recombinant, 
soluble  gp120 antiserum PB26 (50) from Genentech Inc. (South 
San Francisco,  CA); and rabbit anti-recombinant, soluble gp120 
antiserum R1/87 from R. S. Daniels (National Institute for Med- 
ical Research, London, UK). 
Cell Culture and Virus Infection.  H9 cells (from R. Gallo, Na- 
tional Institutes of Health, Bethesda, MD) were cultured in growth 
medium, RPMI 1640/10% FCS, in the presence of 5% CO2. In- 
fection of H9 cells with supernatant containing infectious virus 
of the Hxl0 clone of HIV-1  (from B. Hahn, University of Ala- 
bama, Birmingham, AL; 51) was as follows:  One million cells in 
1 ml were exposed to 104 50% tissue  culture infectious doses of 
virus-containing supernatant for 2 h at 37~  After washing, the 
cells were resuspended in growth medium and cultured for 6-8 d. 
At this time 100% of the cells expressed  large amounts of viral 
envelope  glycoproteins but no CD4 as detected by indirect im- 
munofluorescent staining with mAbs to domain 1 and domain 4 
of CD4 and by flow cytometric analysis. 
Analysis of  Antibody Binding by Flow Cytometry.  H9 cells infected 
with Hxl0 virus as described above were washed twice in RPMI 
1640/5% FCS and were resuspended at a concentration of 2  x 
106 cells/ml.  50/zl of mAb previously diluted in PBS/1%  FCS 
(wash buffer [WB]) were added to 50 #1 of cell suspension  in a 
U-bottomed, 96-well microtiter plate and incubated with agita- 
tion at 37~  for 2 h. The cells were washed three times in WB 
and then fixed in WB plus 2% formaldehyde overnight at 4~ 
After two further washes in WB, an appropriate dilution of fluoro- 
chrome-conjugated second layer antibody was added: anti-human 
PE or anti-mouse PE (obtained from Immunotech Inc., Marseille, 
France), or anti-rabbit PE (Sigma Chemical Co., St. Louis, MO). 
The cells were washed twice as before and then analyzed by flow 
cytometry using a FACScan  |  with Consort 30 software (Becton 
Dickinson and Co.,  San Jose, CA). 
Kinetic Analysis ofmAb Binding.  The kinetic analysis of mAb 
binding to cell surface antigens using indirect immunofluorescence 
and flow cytometric analysis has been previously described  (52). 
We have adopted a similar  strategy to estimate the rates of mAb 
association and dissociation  and their relative affinities. To estimate 
the rate of association,  we determined the tl/2 required for the 
mAbs to reach equilibrium binding conditions. Although this is 
not a formal measurement of the mAb association constant, it serves 
to give an indication of the on-rate, mAbs were diluted in RPMI 
1640/5% FCS, added to 1@ H9 cells/well of a U-bottomed 96- 
well microtiter plate to give final concentrations of 10, 1, 0.1, or 
0.01/~g/ml in a total volume of 100 #1, and incubated with agita- 
tion at 37~  At the times indicated,  10/~1 (10  s cells) were diluted 
20-fold in ice-cold WB, centrifuged to remove excess mAb, and 
then resuspended in WB plus 2% formaldehyde.  After overnight 
fixation, the cells were washed twice as before and then resuspended 
in the appropriate dilution of anti-species  IgG-PE conjugate.  Cells 
were agitated for 2 h  at 4~  and then washed and analyzed by 
flow cytometry as described above. To estimate the rate of dissocia- 
tion, mAbs at 50 #g/ml were incubated with 1@ cells in 100 #1 
RPMI 1640/5% FCS for 2 h at 37~  with agitation to achieve 
maximum binding, and then washed twice and resuspended in 100 
#1 of RPMI 1640/5% FCS and incubated with agitation at 37~ 
At the time points shown in Fig. 5, 10/~1 of cell suspension  was 
removed and fixed in a 20-fold volume of ice-cold WB/2% formal- 
dehyde overnight at 4~  The following day the cells were washed, 
stained  with PE conjugate, and analyzed as described  above. 
ELISA Assays  for mAb Binding and Measurement  of mAb-induced 
gp120 Dissociation.  mAb binding assays were carried out using 
purified recombinant gp120 molecules derived from the BH10 mo- 
lecular clone of the HIV-1 LAI isolate. The BH10 glycoprotein ex- 
pressed in Chinese hamster ovary cells was batch 42 prepared by 
Celltech Ltd. (Slough, UK) (48) and obtained from the UK Med- 
ical Research Council AIDS Directed Programme. BH10 gp120 
is of the same primary sequence as gp120 in the infectious molec- 
ular clone Hxl0. The detection ofmAb binding in an ELISA format 
was essentially  as described  elsewhere  (23).  Briefly, recombinant 
gp120 was captured onto a solid phase  via its COOH terminus 
using sheep polyclonal antibody D7324. The gp120 was added at 
25 ng/ml in Tris-buffered saline (TBS) containing 10% FCS. mAbs 
were added to the gp120 in TBS containing 2% nonfat milk powder 
and 20% sheep serum. Bound mAb was detected as previously de- 
scribed (23).  No detergent was used at any stage to ensure that 
the native folding of the glycoprotein was not perturbed. Release 
of gp120 from the surface of Hxl0-infected, mAb-treated cells was 
determined as follows: Three hundred thousand cells in 30/~1, pre- 
viously incubated at 37~  for 4 h with prebound mAb as described 
above for the mAb dissociation studies, were pelleted.  The super- 
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microfilters (Spin-X; Costar, Brumath, France) to remove  remaining 
cells and cell debris, and 3 #1 of a 10% solution of NP-40 was added. 
To prevent interference with the gp120 detection, the samples were 
denatured to eliminate prebound mAb. To do this, SDS and DTT 
were added to 20 #1 of supernatant to yield final concentrations 
of 1% and 50 raM, respectively.  After boiling, the treated superna- 
tants were diluted in 180 #1 of TBS/FCS (10%)/NP-40  (1%). 100 
#1 was then added to duplicate wells of an ELISA plate precoated 
with the gp120 capture antibody D7324. The detection and cali- 
bration of denatured gp120 in the supernatant was carried out as 
previously described using the routine mAb B13 (from G. Lewis, 
University of Maryland Medical School, Baltimore, MD), which 
reacts preferentially with denatured gp120 (28). B13 recognizes a 
continuous  epitope in the gp120 C2 domain (28). 
HIV Neutralization Assays.  To compare mAbs for neutraliza- 
tion activity, we used an assay based on infection of HeLa cells 
expressing human CD4 and the HIV LTK gene fused to lacZ (53). 
Infection of these cells with HIV leads to the production of the 
viral TAT protein, which transactivates the transfected LTR and 
activates the lacZ gene; addition of 5-bromo-4-chloro-3-indolyl-3- 
D-galactopyranoside (X-Gal; Gibco BRL, Gaithersburg, MD) then 
results in blue coloration of the infected cells. The advantage of 
this assay system is that infection of the cells  can be detected within 
16 h of infection (one cycle of replication), and the infected cells 
can be easily quantified by visual inspection. 20 #1 of a previously 
titrated suspension of HIV containing ,~200 infectious U for the 
HeLa-CD4-LTR LacZ  cells was preincubated with dilutions of the 
mAbs in DME/5% FCS for 2 h at 37~  in a total volume of 40 
~1 before addition of 10 #1 of HeLa cells at a concentration of 5 
x  106 cells/ml. After 1 h incubation at 37~  with agitation, the 
cells were washed in PBS/10 mM EDTA and incubated with EDTA- 
trypsin  (Gibco  BRL)  for  15  min  at  37~  After  washing  in 
DME/5% CS, the cells were cultured overnight in flat-bottomed 
96-weU microtiter plates. The following day the cells were fixed 
with 1% formaldehyde for 10 min and then stained in a solution 
of X-Gal for 4 h at 37~  Cells were then washed once in WB 
and fixed overnight in WB/2% formaldehyde. Blue-stained cells 
were counted by eye at a magnification of 100. 
Results 
Binding of Neutralizing Antisera  to HIV-infected  Cells and 
Recombinant gpl20.  HIV-reactive polyclonal antisera obtained 
either from  seropositive individuals  or  from  animals  im- 
munized with recombinant gp120 are neutralizing for HIV-1 
in vitro (54). The reactivity of immune sera with gp120 is 
generally measured using recombinant or purified gp120 in 
a monomeric form by techniques such as ELISA or Western 
blotting. Since our aim was to measure the binding of neu- 
tralizing antibodies to functional, virion-associated gp120, 
it seemed appropriate to compare antiserum reactivity with 
monomeric gp120 in ELISA with that with infected, cell- 
associated  gp120. To do this we stained the H9 T  cell line 
infected with the LAI molecular clone Hxl0 with the different 
antisera listed in Table 1 and detected antibody binding by 
indirect immunofluorescence and flow cytometric analysis as 
previously described (55, 56). The binding of a panel of an- 
tisera of human or rabbit origin either to infected cells or 
to recombinant BH10 gp120 in ELISA are shown in Fig. 1, 
A  and B, respectively. In ELISA, saturation binding for the 
Table 1.  Antibodies Used in This Study 
Antibodies 
Antisera 
Name  Antigen*  Species  Reference 
QC2,  QCS, QC6  Virion  Human  50 
LWS  Virion  Human  51 
K1/87  rgp120  Rabbit 
PB26  rgp120  Rabbit  52 
mAbs of murine  origin 
Location  Name  Antigen  Epitope*  References 
V2  BAT085  pgp120  169-180  18,  19 
G3-136  pgp120  169-183  18,  19 
G3-4  pgp120  170-180  17,  19 
V3  8/38c  rgp120  300-315  16 
9284  Virion  301-312  8 
BAT123  pgp120  308-322  4,  12 
110.5  pgp120  310-317  9 
110.I  rgp120  316-322  28 
C4  Group  pgp120  429-438  21,  23 
mAbs of human  origin 
Location  Name  Antigen  Epitope  References 
CD4 B/SS  15e  Virion  Discontinuous  24, 25 
21h  26 
Complexll  48d  Virion  Discontinuous  27 
17b  27 
* Immunizing antigens are defined  as follows:  virion, serum or mAb ob- 
tained from an HIV-seropositive  individual; rgp120, recombinant,  solu- 
ble gp120; pgp120, gp120 purified from virions. 
Epitope refers  to the sequence numbering of the HXB2 molecular  clone 
taken from the Los Alamos database 1992. 
S CD4 B/S, a discontinuous epitope that overlaps  but is not identical to 
the CD4 binding site on gp120. 
II Complex, a complex, discontinuous  epitope, binding of mAbs to which 
does not interfere with CD4 binding. 
human sera was achieved at dilutions of between 1/100 and 
1/300, and, for the rabbit sera, at ~1/100. By contrast, satu- 
ration was not achieved with these sera in the infected cell 
system, and the binding curves were dearly displaced towards 
the right, suggesting lower avidity of the anti-HIV-1 anti- 
bodies for membrane-bound gp120  than  for recombinant 
gp120. Most striking was the very poor binding of the two 
rabbit antisera to the infected cells compared with the recom- 
binant glycoprotein. Although the two assays used are not 
easily comparable in terms of absolute numbers of gp120 mol- 
ecules expressed, it seemed unlikely that quantitative differ- 
ences in the amount of gp120 present in each system could 
explain the large differences in the serum binding. Although 
these data suggest that there are differences in the binding 
of anti-gp120 antibodies to monomeric gp120 as compared 
187  Sattentau  and Moore 0 
0 
c 
M 
0 
m 
gl 
O~ 
C3 
O 
300- 
250 ￿9 
200- 
150 ￿9 
100" 
5O 
0 
,01 
A 
QC2 
￿9  R,,8,  //// 
￿9 
....... i  ........ i  .... u  ........ i 
01  1  18  100 
200 " 
1,5" 
1,0 ￿9 
0,S' 
0,0 
B 
A 
m 
e- 
C  m 
sum.  .  .  ￿9  Inn  ....  ~  ........  U  .......  ~  ......  9 
,01  ,1  1  10  100  1000 
Serum  dilution  (1/x  X  10-4) 
Figure  1.  Binding of neutralizing antisera to recombinant  and cell sur- 
face gp120.  For cell surface staining  (A), HIV-l-infected cells were in- 
cubated with dilutions of the antisera for 2 h at 370C,  washed,  and then 
stained with the appropriate  antibody-fluorochrome conjugate for 1 h at 
4~  After washing and fixation in formaldehyde, the samples were ana- 
lyzed by flow cytometry using Consort 30 software. Each point represents 
the mean fluorescence intensity for 10,000 accumulated  events. Analysis 
of mAb binding to recombinant gp120 (BH10) captured by an mAb reac- 
tive with the COOH-terminal residues onto the solid phase was done 
by ELISA (B).  Results  are expressed as the optical  density  at 492 nm. 
The symbols  represent  the same antisera in both A  and R 
with functional, multimeric gpl20, there are factors that com- 
plicate their interpretation. Polyclonal antisera derived from 
infected individuals contain antibodies reactive with several 
viral proteins, including gp41 and the HIV core proteins p18 
and p24, all of which can be detected on the surface of in- 
fected ceils (57, 58). Such antisera also contain cell surface- 
specific reactivity (for review, see reference 59), although this 
was found to be a minor component of the signal since unin- 
fected H9 cells stained very weakly or undetectably with these 
sera (data not shown). Antiserum reactivity with molecules 
other than gp120 on the cell surface  would increase the overall 
level of staining but dilute the gp120-specific signal,  thus 
decreasing the apparent  difference between cell surface and 
recombinant gp120. We therefore decided to dissect out the 
various components of the gp120 neutralizing humoral im- 
mune response present in the sera using mAbs of defined 
specificity. 
Binding of Neutralizing mAbs to Hll/:infected Cells and Recom- 
binantgp120.  The spectrum of neutralizing epitopes on HIV-1 
gp120 is broadly represented by the five clusters of mAbs listed 
in Table 1. These mAbs are of murine, rat, or human origin 
and were selected as representative of a variety of different 
epitopes within each cluster. Each of the mAbs listed has been 
previously characterized in terms of soluble gp120 binding, 
epitope specificity, and to some extent HIV-1 neutralization 
activity. Little is known, however, about their ability to in- 
teract with natively folded, gp41-associated, multimeric gp120. 
Here we have compared the binding of these mAbs to recom- 
binant gpl20 in ELISA  with their binding to multimeric gpl20 
present on HIV-infected cells (Fig. 2). Saturation binding to 
monomeric gpl20 in F_LISA  was achieved  with all mAbs tested 
within a concentration range of 1-10 nM. By contrast,  satu- 
ration binding to cell surface gpl20 was observed only with 
the V3 mAbs at concentrations  between 1 and 3 nM, and 
with certain human mAbs reactive  with complex and CD4/B5 
epitopes at concentrations of 30-100 nM. None of the mAbs 
in the V2 or C4 groups achieved equilibrium binding under 
the experimental conditions used. The ability of V3 mAbs 
to saturate gpl20 molecules expressed at the cell surface at 
concentrations comparable to those required to saturate mono- 
meric gpl20 implies that the variation in mAb binding be- 
tween monomeric and cell surface gpl20 is unlikely to simply 
reflect different numbers of gpl20 molecules in the two sys- 
tems; there is clearly a substantial difference between certain 
of the mAb groups in the strength of their interactions with 
the two forms of gpl20. We tested concentrations  of up to 
1,334 nM (200/~g/ml) yet were still unable to achieve satu- 
ration binding with the V2 and C4 mAbs (data not shown). 
The  poor  affinity  of the  non-V3  mAbs  for  membrane- 
associated gpl20 is clear from the results presented in Table 
2. To obtain an estimate of the relative affinities of the mAbs, 
we calculated the half-maximal binding values for each mAb 
for which saturation  was achieved and estimated the min- 
imal values for those with which we were unable to obtain 
saturation. The difference  in these values between monomeric 
and oligomeric gpl20 mAb binding varies between none (V3 
mAb 110.I) and >350-fold  (V2 mAb G3-4). 
mAb Binding Kinetics.  It is unclear from the data presented 
in Fig. 2 whether the poor mAb binding to multimeric gp120 
results from (a) a slow association rate; (b) a rapid dissocia- 
tion rate; (c) a combination of the two factors; or (d) mAb 
binding inducing a conformational change in gp120 leading 
to gp120-gp41 dissociation. This latter possibility would give 
rise to the impression that mAb affinity was artificially low, 
as has been previously demonstrated for sCD4  binding to 
virion gp120 (2). The measurement ofmAb binding kinetics 
to cell membrane-anchored molecules by indirect immuno- 
fluorescent staining and flow cytometric  analysis  has been pre- 
viously described (52). Using similar methodology, we have 
estimated the relative rates of association and dissociation of 
each of the mAbs for multimeric, virion-associated gp120. 
Because  we were unable to accurately measure the initial rates 
of mAb association using this system, we have determined 
the tl/2 for each mAb to  reach equilibrium  binding.  Al- 
though this does not yield a formal measurement of the mAb 
association constant, it serves to give an indication of the 
on-rate, assuming that the dissociation rate is similar for all 
mAbs. Fig. 3 shows the binding of mAbs from each of the 
epitope groups to cell surface gp120 at different times after 
addition.  There are obvious differences in the cell binding 
188  HIV Neutralization and Epitope Exposure .= 
t- 
1,0' 
,0, 
,0, 
0 
,001  ,01 
V2 
~-  BAT~ 
,1  1  10  1001000 
160 
140 
120 
1(;(I 
,0 
,0 
40 
20 
0 
,001  ,01 
V3 
,1  1  10  1001000 
1,0" 
140" 
120- 
1,0" 
,0. 
,0- 
40- 
20- 
G3-299 
G3-42 
A  G3-$19 
~  .:T-;  ...............  01  10  1001000 
1,o- Complex 
14o~ 
120i  ~  171) 
i  ~  484 
100-  ,~,  15e 
':'  ￿9  ,lh 
,1  I  10  100  1000 
O4 
O)  ,q. 
s 
O 
1.6'  G3-4 
1,4'  G3-136 
1,0 
0,8 
0,6 
0,4 
0,2 
0,•  ,  .....  T  ......  ~  ......  ~  ....  ~  ....  ~ 
,001  ,01  ,1  1  10  100 
1,8 
1,6 
1A 
1,2 
1,0 
0,8 
O,6 
0A 
0,2 
0,0 
,01 
V3 
J~  BAT123 
,1  1  10  100 
mAb 
1,0  C4 
1,0"  ~~.~9 
1,4" 
1,2" 
1,0" 
0,0 ~ 
0,6' 
0,4' 
0,2' 
0,0  - 
,01  ,1  1  10  100 
concentration  (riM) 
1,0 
1,6 
1,0 
1,2 
1,0 
0,8 
0,0 
0.4 
0,2 
0.0 : 
,01 
Complex 
21h 
""{3"--  150 
2Y 
,1  1  10  100 
Figure  2.  Binding of neutralizing mAbs to recombinant  and cell surface gpl20. (%p) HIV-infected cells were stained for mAb binding by indirect 
immunofluorescence  and analyzed by flow cytometry as described in Fig.  1.  (Bottom) mAb binding to recombinant  gp120 in ELISA was carried out 
as described in Fig.  1. 
Table  2.  mAb Binding and Neutralization  Parameters 
Half-maximal binding 
Region  mAb  Monomer*  Oligomer*  Neutralization  Association  Dissociation 
nM  IDso in nM  ti/2 (rain)  tl/2 (rain) 
V2  G3-136  0.4  >20 s  7.7  40  >240 II 
G3-4  0.2  >70  44.4  >601  >240 
BAT085  1.0  >70  133.4  >60  200 
V3  110.5  0.07  0.05  0.2  <5  240 
9284  0.07  0.12  0.93  <5  240 
BAT123  0.08  0.08  0.13  <5  240 
110.I  0.45  0.5  1.3  10  240 
8/38c  10  66.7  66.7  30  100 
C4  G3-299  1.0  >50  4.1  40  240 
G3-519  1.0  >50  98.4  >60  >240 
G3-536  1.2  >50  266.8  >60  120 
G3-508  1.2  >50  186  >60  240 
G3-42  0.3  >50  ND  >60  240 
CD4/BS  15e  2.5  20  4.8  20  >240 
21h  2.5  20  6.0  30  >240 
Complex  48d  2.5  5.0  1.3  20  120 
17b  2.0  >80  50  >60  240 
* Monomeric, recombinant gp120  was captured  onto the solid phase and  screened for mAb binding by ELISA. 
* Multimeric gp120  was in the form of the HIV envelope  glycoproteins  expressed at the surface of infected  cells. 
S Minimum half-maximal  binding values could not be calculated for mAbs with which saturation  staining  was not achieved;  results  are the mean 
of at least  two separate  experiments. 
II Minimum rates  of dissociation  could not be calculated  for mAbs that did not reach  50%  dissociation  within the time of the experiment. 
￿82  Minimum and  maximum rates  of association  could not be accurately  determined  for mAbs that reached  equilibrium much faster  than we were 
able to measure  or that did not reach  equilibrium within the time of the experiment, respectively. e- 
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Figure 3.  mAb association  rates. HIV-infected  cells  were 
incubated with mAbs at 37~  for different times before 
washing and fixation. Cells were then stained with the 
appropriate anti-species Ig coupled to PE before analysis 
by flow  cytometry  as described  in Fig. 1. The mAb binding 
curves shown in this figure were carried out using a con- 
centration of 10/tg/ml. 
kinetics of the mAb clusters; the majority of V3 loop mAbs 
reach equilibrium binding in <5 rain  (the first measurable 
time point), whereas the other mAbs require 1-2 h or longer. 
The tl/2 values for each mAb to reach equilibrium binding 
are shown in Table 2.  There is a spectrum of rates ranging 
from <5 min to >1 h.  A  comparison of the values for the 
half-maximal  binding  and  the  tl/2 to  saturation  for  each 
mAb confirms that there is a broad relationship; those mAbs 
with the highest relative affinity for oligomeric gpl20 (V3, 
CD4 binding site mAbs, and mAb 48d) have the fastest esti- 
mated on-rates, whereas those with the lowest relative affinity 
(V2, C4, and mAb 17b) have the slowest on-rates. By con- 
trast, there was no overall relationship between the rates of 
dissociation and the relative affinity of each mAb for oligo- 
meric gp120.  Fig. 4 shows the dissociation curves for each 
group of mAbs; all mAbs had similar dissociation kinetics 
with the exception of four: BAT085 (V2), 8/38c (V3), G3-536 
(C4), and 48d (complex). It should be noted that, since the 
dissociation rate is higher  than for the other mAbs tested, 
the  estimated  relative  tl/2 for  the  association  of  mAbs 
BAT085,  8/38c,  G3-536,  and 48d will be underestimated. 
The  half-maximal  dissociation rates  are presented in Table 
2. A few of the mAbs with very low affinity for the monomer, 
such as 8/38c and BAT085, have relatively rapid dissociation 
kinetics, suggesting that the rate of dissociation from oligo- 
meric gpl20 may influence the relative affinity of a minority 
of mAbs. 
The apparent  mAb affinity will be influenced by loss of 
gp120 from the cell surface; gp120 and gp41 from cell line-pas- 
saged HIV-1 dissociate spontaneously at 37~  (for review see 
reference 2), and soluble CD4 binding increases this dissoci- 
ation (55, 56; for review see reference 2). Since we were in- 
terested only in the relative differences between mAbs, the 
influence of gp120 loss on absolute rates of mAb association 
and dissociation was discounted. It was necessary,  however, 
to determine whether the binding of particular mAbs to gp120 
influenced  the rate of gp120-gp41  dissociation,  since this 
would alter the apparent rates of mAb association/dissocia- 
tion. Fig. 5 shows the quantity of soluble gp120 released after 
4 h of incubation of mAb-precoated, HIV-infected cells. Gp120 
dissociation was modified compared to the basal level in the 
presence of several of the mAbs; the effect in this experiment 
was relatively  subtle,  however,  in  that  the  greatest  mAb- 
induced changes in gp120 dissociation were an  increase  of 
1.3-fold in the presence of mAb 110.I, and a decrease of 1.5- 
fold in the presence ofmAb G3-4. Thus, although the binding 
of certain  mAbs apparently modulates  gp120 dissociation, 
these changes appear to be relatively small and do not influence 
the overall  interpretation  of the results. 
Neutralizing Activity of  gp120 mAbs.  Although all of the 
mAbs described here have previously been characterized  as 
virus neutralizing,  there has not been a systematic study in 
which the same assay system has been used to compare the 
HIV-1 neutralization ability ofmAbs from different clusters. 
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Figure 4.  mAb dissociation  rates. HIV-infected  cells  were preincubated 
with mAbs at 50/*g/ml at 37~  for 2 h before  washing  and reincubation 
at 37~  At the times  shown, aliquots  of cell suspension  were removed, 
washed, and fixed  before  washing, staining,  and analysis  as described for 
Fig. 3. 
Moreover, their binding to oligomeric gpl20 has not been 
compared with their neutralizing capacity.  We have there- 
fore chosen a rapid and quantitative assay of HIV neutraliza- 
tion based on the detection of HIV TAT after infection of 
CD4 §  HeLa cells  containing the HIV LTR fused to the 
LacZ operon (53). Using this assay system, HIV neutraliza- 
tion can be detected within one cycle of virus infection. Virus 
neutralization was measured by preincubation of a pretitered 
HIV stock with various concentrations of the different mAbs 
before addition to the indicator cells. Fig. 6 shows the neu- 
tralization obtained with a selection of the mAbs from the 
five different clusters. All mAbs neutralized virus within ap- 
proximately a three-decade range (0.1-300 nM), confirming 
(with the exception of the V3 mAb 8/38c, which had been 
described as nonneutralizing in the absence of sCD4; 16) their 
previously described neutralization activity. The V3 mAbs 
were dearly the most potent, with all but one mAb giving 
IDs0 values ranging from 0.13 to 1.3 nM (Table 2). Neutral- 
ization was variable within the other groups; V2, C4, and 
conformational clusters  all contained mAbs that gave IDs0 
values of 1-10 nM but also contained mAbs with much weaker 
neutralization activity (50-267  nM).  A comparison of the 
data in Table 2 suggests that there may be a limited correla- 
tion between mAb binding to monomeric gpl20 and neu- 
tralization, in that the V3 mAbs that bind with the highest 
relative affinity have the highest neutralization potency. Out- 
side of this group of mAbs, however,  there is no clear rela- 
tionship. By contrast, there appears to be a general correla- 
tion between mAb neutralization capacity,  relative affinity, 
and estimated rate of association for oligomeric gpl20.  As 
with monomeric gpl20, mAbs from the V3 loop cluster bound 
with the highest relative  affinity to oligomeric gpl20 and 
had the strongest neutralizing activity. Outside of this group 
Figure 5.  mAb-induced  gpl20 dissociation. Cells preincubated with 
mAbs as described for Fig. 4 were washed and reincubated  at 37~  for 
4 h. The cells  were  pelleted,  and the supernatant  was spun  through  0.22-/xm 
filters to remove  cell debris and treated with NP-40, 1% final  concentra- 
tion. Gp120-mAb complexes  in the supernatants  were then denatured  to 
prevent interference  of gp120 detection  by bound Ig, and gp120 concen- 
tration was measured  by ELISA.  Each  bar represents the mean signal ob- 
tained  from  duplicate  ELISA  wells, and the dotted  line  represents  the level 
of spontaneous gpl20 dissociation. 
the pattern was also consistent, in that those mAbs with the 
highest relative  affinities and the fastest rates of association 
were the best neutralizers, and those with lower relative affini- 
ties and slower rates  of association were the poorest neu- 
tralizers. 
Discussion 
In this study we report that antibody binding to mono- 
meric gpl20 does not necessarily reflect the level of antibody 
binding to multimeric, gp41-associated virion gpl20, and that 
the efficiency of mAb binding to oligomeric gpl20 is a good 
indicator of  mAb potency as a neutralizing agent. Several  points 
arising from these data have implications for vaccine design 
and testing. 
Our results indicate that, whereas immune antisera raised 
against live virus during infection with HIV-1 bind well to 
recombinant gpl20, they bind considerably less well to oligo- 
meric, gp41-associated gpl20, This implies that a large propor- 
tion of the antibody response  to HIV infection is against 
regions of gp120  that are poorly exposed on the oligomer, 
i.e., most regions other than the V3 loop. This is in agree- 
ment  with data previously published by our laboratories 
demonstrating that the antibody specificities most prevalent 
in human antisera are those to discontinuous cross-reactive 
epitopes,  in particular the CD4 binding site (60). Moreover, 
we and others have recently demonstrated that certain non- 
neutralizing mAb epitopes that are present on recombinant, 
soluble gp120 are completely or partially obscured on oligo- 
meric gp120 (28, 61). It seems likely that this explains at least 
in part the poor reactivity for oligomeric gp120 of the rabbit 
antisera raised against recombinant gp120; such antisera contain 
a large proportion of antibodies that will react preferentially 
with the monomeric glycoprotein. The reason for the loss 
of epitopes on native, oligomeric gp120  may be the result 
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Figure  6.  mAb neutralization  of HIV-1. A  stock  of 
virus previously titered on HeLa-CD4-LTR LacZ cells and 
known to give 200 infected cells/well in 20/zl was in- 
cubated for 2 h with mAbs at the concentrations  shown 
in the figure before washing and trypsinization  to remove 
noninternalized  virions. The cells were subsequently cul- 
tured for 24 h at 37~  before fixation and staining with 
X-Gal for 4 h at 37~  The cells were then fixed over- 
night,  and  the  blue  loci were counted  by  eye under 
magnification.  Each point represents the mean of tripli- 
cate wells, and  the vertical bars indicate  +_ 1 SD. 
of one or several  of the following factors: (a) epitope masking 
by gp120-gp41  association; (b) epitope masking by gp120- 
gp120  association;  (c) condensation of the folded protein 
leading to epitope masking by carbohydrate groups;  or (d) 
alteration of epitope conformation after oligomeric folding 
and gp41 association. Whatever the molecular basis of the 
difference in epitope exposure,  these data suggest  that the 
use of recombinant, soluble, monomeric glycoprotein for vac- 
cine immunization is likely to shift the immune focus away 
from neutralizing epitopes present on the oligomer to less 
relevant epitopes present on the monomer. The effect of this 
will be to induce a large proportion of the antibody response 
to epitopes that are poorly represented on the virion surface. 
The sole exception to this may be the V3 loop, which is well 
exposed on both the oligomeric and monomeric forms of 
the T cell line-adapted virus that we have studied. However, 
one recent study (61) presented evidence that immunization 
of mice with  soluble,  gp41-associated  oligomeric gp120 
resulted in a low frequency of V3 loop reactivity, suggesting 
that the V3 loop may not be an immunodominant domain 
in oligomeric gp120. This conclusion is in accord with the 
fmding that the V3 loop of a monocytotropic HIV-1 primary 
isolate appears to be cryptic on the virion surface (62). Such 
masking of V3 epitopes on non-cell line-passaged virus may 
explain our recent observation that HIVol primary isolates 
are relatively poorly neutralized by V3 mAbs, which are po- 
tent neutralizers of T  cell line-adapted viruses such as the 
Hxl0 clone used in the present  study (63, 64). 
Antibody affinity is determined by the ratio between the 
association and dissociation rate constants.  It had until re- 
cently been considered that the dissociation rate was the major 
determinant for almost all mAbs, although this assumption 
was based on the study of antibodies with small synthetic 
haptens (52). More recent work, in which antibody binding 
to more complex antigens such as membrane-anchored  mol- 
ecules has been analyzed, suggests that the association rate 
may play an equal or greater role in determining affinity (52). 
Our study is in accord with this latter conclusion, since the 
estimated association rate of mAbs for oligomeric gpl20 ap- 
pears to be the major factor influencing affinity. Interestingly, 
another group has demonstrated that the major determinant 
in mAb binding to the V3 loop of soluble, recombinant gpl20 
is the dissociation rate (65). Thus, antigens may react very 
differently with antibodies depending on their presentation; 
in this case soluble monomeric  forms compared with the more 
physiologically  relevant,  membrane-anchored,  oligomeric 
forms. One interpretation of these differences is that, on the 
complex, oligomeric form of the viral envelope glycoprotein, 
many epitopes that are potentially capable of high affinity 
interactions with an antibody are shielded from that anti- 
body. Thus, the rate at which an antibody can gain access 
to these sites will dominate the parameters of the binding 
and neutralization  reaction. On monomeric forms of these 
proteins or on peptide fragments, epitope accessibility  is often 
a less important factor, and the dominant influence on the 
antibody-antigen affinity is, as is commonly found, the dis- 
sociation rate. We have not, however, measured mAb binding 
kinetics for the monomeric  form of gp120 in the present study 
and are thus unable to make a direct comparison of the two 
forms of the glycoprotein with the panel of mAbs used. A 
confounding factor in the measurement and interpretation 
of mAb binding to gp41-associated  gp120 is the phenomenon 
of gp120-gp41  dissociation (55, 56). We have determined 
the dissociation of gp120 from infected cells in the presence 
192  HIV Neutralization and  Epitope  Exposure and absence of prebound mAbs and note that  the binding 
of certain mAbs does appear to influence dissociation (Sat- 
tentau, Q., unpublished data, and see Fig. 5). While this ob- 
servation does not invalidate our conclusions regarding mAb 
binding to oligomeric gp120, it suggests that mAb binding 
may induce conformational changes in gp120 that  are akin 
to those induced by sCD4 (55, 56). Documenting this phe- 
nomenon  more precisely and determining  its contribution 
to virus neutralization are subjects of our further investigation. 
The rate of antibody association with a viral glycoprotein 
will clearly influence the ability of that antibody to neutralize 
virus in vivo as well as in vitro. The release of an HIV virion 
from a cell will be followed by the binding  of that  virion 
to its receptor on another cell. If the on-rate of a neutralizing 
antibody is in the order of seconds, then there is a good chance 
that  the virus will be successfully neutralized.  If, however, 
the tl/2 for equilibrium binding is of the order of hours or 
even minutes,  as is the case for many of the mAbs studied 
here, then the virus will have a strong possibility of escaping 
neutralization by infecting a target cell. This scenario is par- 
ticularly relevant in the case of HIV-1, where virus is released 
in large quantities into the lymphoid tissue where CD4 § T 
cells are densely packed (59). Any reduction in the on-rate 
of an antibody-antigen  interaction  could yield a profound 
selective advantage  to HIV replication  in vivo (63). 
Our demonstration of a broad correlation between mAb 
binding to oligomeric gp120 and HIV-1 neutralization  im- 
plies that  mAb affinity may be the primary neutralization 
determinant,  regardless of the mechanism of viral inactiva- 
tion. Exceptions to this relationship may exist, however; Stern 
et al. (66) have recently shown that neutralization sensitivity 
of a mutant compared to the wild-type clone of HIV-1 did 
not correlate with mAb binding to oligomeric gp120. This 
suggests that in certain cases mAb binding affinity may be 
secondary  to  other  factors  in  determining  neutralization 
efficiency.  The nature  of such factors is currently obscure. 
The binding and neutralization  data that we report here 
have all been carried out on a single virus done derived from 
the prototype LAI isolate of HIV-1 (51). This virus was iso- 
lated, and has been passaged extensively, in immortalized T 
cell lines.  HIV-1 passage in cell lines as opposed to primary 
lymphocyte cultures has been shown to alter the biological 
properties of HIV-1 virions;  they become more fusogenic, 
have a higher affinity for CD4, and are more easily neutral- 
ized (2, 59, 63). Preliminary evidence from our laboratory 
indicates  that  the  relative  resistance  of primary  lympho- 
cyte-passaged HIV to neutralization may be due to an even 
more profound masking of epitopes on the oligomeric form 
of gp120 (Sattentau,  Q., unpublished data).  Study of mAb 
binding to oligomeric forms of the envelope glycoproteins 
of these and other viruses will yield valuable information on 
mechanisms  of neutralization. 
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